MedTrace Logo

LC Bead Embolization Agent With Doxorubicin in the Treatment Liver Metastasis From Melanoma

NCT01010984 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2018-10-25

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine if LC beads loaded with Doxorubicin are a safe and effective treatment for melanoma that has spread to the liver.

Conditions

  • Stage IV Melanoma

Interventions

DEVICE

LC beads loaded with Doxorubicin

During each TACE, 2 vials (1 vial, 75mg Doxorubicin) of 100-300 micrometer size LC beads loaded with doxorubicin will be delivered to the liver tumor(s). Total Doxorubicin dose for each TACE is 150mg

Sponsors & Collaborators

  • University of Louisville

    collaborator OTHER

  • Thomas Jefferson University

    collaborator OTHER

  • M.D. Anderson Cancer Center

    collaborator OTHER

  • Robert C. Martin

    lead OTHER

Principal Investigators

  • Robert CG Martin, MD, PhD · University of Louisville

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-09-30
Primary Completion
2012-12-31
Completion
2012-12-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01010984 on ClinicalTrials.gov